Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An update on corticosteroid treatment for IgA nephropathy.
Ghaddar M, Barratt J, Barbour SJ. Ghaddar M, et al. Among authors: barratt j. Curr Opin Nephrol Hypertens. 2023 May 1;32(3):263-270. doi: 10.1097/MNH.0000000000000881. Epub 2023 Mar 2. Curr Opin Nephrol Hypertens. 2023. PMID: 36866805 Review.
The MEST score provides earlier risk prediction in lgA nephropathy.
Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. Barbour SJ, et al. Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322. Kidney Int. 2016. PMID: 26759049 Free article.
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. Among authors: barratt j. Kidney Int. 2020 Oct;98(4):1009-1019. doi: 10.1016/j.kint.2020.04.042. Epub 2020 May 25. Kidney Int. 2020. PMID: 32464215 Free article.
Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy.
Canney M, Barbour SJ, Zheng Y, Coppo R, Zhang H, Liu ZH, Matsuzaki K, Suzuki Y, Katafuchi R, Reich HN, Cattran D; International IgA Nephropathy Network; International IgA Nephropathy Network Investigators. Canney M, et al. J Am Soc Nephrol. 2021 Feb;32(2):436-447. doi: 10.1681/ASN.2020030349. Epub 2020 Dec 23. J Am Soc Nephrol. 2021. PMID: 33514642 Free PMC article.
IgA nephropathy: an overview of drug treatments in clinical trials.
Selvaskandan H, Gonzalez-Martin G, Barratt J, Cheung CK. Selvaskandan H, et al. Among authors: barratt j. Expert Opin Investig Drugs. 2022 Dec;31(12):1321-1338. doi: 10.1080/13543784.2022.2160315. Epub 2023 Jan 1. Expert Opin Investig Drugs. 2022. PMID: 36588457 Review.
Long-Term Outcomes in IgA Nephropathy.
Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Pitcher D, et al. Among authors: barratt j. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. Clin J Am Soc Nephrol. 2023. PMID: 37055195 Free PMC article.
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. Barratt J, et al. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180506 Free PMC article.
484 results